¼¼°èÀÇ ¸ÖƼÇ÷º½º Áø´Ü ½ÃÀå
Multiplexed Diagnostics
»óǰÄÚµå : 1737282
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 382 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¸ÖƼÇ÷º½º Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 286¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 136¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸ÖƼÇ÷º½º Áø´Ü ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 13.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 286¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â±â ¹× ¾×¼¼¼­¸®´Â CAGR 11.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 154¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ŰƮ ¹× ½Ã¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 16.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 37¾ï ´Þ·¯·Î ÃßÁ¤¡¤Áß±¹Àº CAGR 17.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸ÖƼÇ÷º½º Áø´Ü ½ÃÀåÀº 2024³â¿¡ 37¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 60¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 17.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 9.8%¿Í 11.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¸ÖƼÇ÷º½º Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸ÖƼÇ÷º½º Áø´ÜÀÌ ÀÓ»ó ¹× POC °Ë»ç¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯

¸ÖƼÇ÷º½º Áø´ÜÀº ÇϳªÀÇ »ý¹°ÇÐÀû »ùÇÿ¡¼­ ´Ü¹éÁú, ÇÙ»ê, º´¿øÃ¼ µî ¿©·¯ ºÐ¼®¹°À» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ºÐ¼® Ç÷§ÆûÀ» ¸»ÇÕ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº Áø´Ü È¿À²À» Å©°Ô Çâ»ó½Ã۰í, ½Ã°£À» ´ÜÃàÇϰí, »ùÇà ¾çÀ» Àý¾àÇϱ⠶§¹®¿¡ °¨¿° °Ë»ç, Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ °Ë»ç, ¾à¸®À¯ÀüüÇп¡¼­ Á¡Á¡ ´õ ¸Å·ÂÀûÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ´õ ºü¸£°í, ´õ Æ÷°ýÀûÀ̸ç, ´ú ħ½ÀÀûÀÎ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ´ÙÁßÈ­ ±â¼úÀº Áß¾Ó ÁýÁᫎ ½ÇÇè½Ç°ú ºÐ»êÇü POC(Point-of-Care) ¸ðµÎ¿¡¼­ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

±âÁ¸ÀÇ ´ÜÀÏ ºÐ¼® Ç׸ñ °Ë»ç¿¡ ºñÇØ ¸ÖƼÇ÷º½º ºÐ¼®Àº Áø´Ü ¼öÀ²À» Çâ»ó½ÃŰ°í º´ÅÂÀÇ ¿©·¯ ¿øÀÎÀ» µ¿½Ã¿¡ °Ë»çÇÏ´Â ÁõÈıº °Ë»ç Á¢±Ù¹ýÀ» Áö¿øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, È£Èí±â ¸ÖƼÇ÷º½º ÆÐ³ÎÀº ÀÎÇ÷翣ÀÚ, SARS-CoV-2, RSV ¹× ±âŸ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ¾î ½Ç½Ã°£À¸·Î Ä¡·á ¹æÄ§À» °áÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â Àü¿°º´ÀÌ À¯ÇàÇÒ ¶§³ª ¸é¿ª·ÂÀÌ ¾àÇÑ È¯ÀÚ Áý´Ü¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Á¤¹ÐÀÇ·á¿Í °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨·Î ÀüȯÇÏ´Â °¡¿îµ¥, ¸ÖƼÇ÷º½º Áø´ÜÀº ´õ ¸¹Àº µ¥ÀÌÅ͸¦ ´õ ³·Àº °Ë»ç ºñ¿ëÀ¸·Î ´õ ºü¸¥ ÀÓ»óÀû ÆÇ´Ü ÁÖ±â·Î Á¦°øÇÒ ¼ö ÀÖ´Â ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ´ÙÁßÈ­ ´É·Â°ú ÀÓ»óÀû À¯¿ë¼ºÀ» Çâ»ó½Ã۰í Àִ°¡?

¸¶ÀÌÅ©·ÎÀ¯Ã¼°øÇÐ, ¹ÙÀÌ¿À¼¾¼­ ¼ÒÇüÈ­, ·¦¿ÂĨ Ç÷§Æû, µðÁöÅÐ °ËÃâ ±â¼úÀÇ Çõ½ÅÀº ·ç¹Ì³Ø½º ºñµå ±â¹Ý ½Ã½ºÅÛ, PCR ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, Â÷¼¼´ë ½ÃÄö½Ì(NGS), Àü±âÈ­ÇÐ ¹ÙÀÌ¿À¼¾¼­´Â °í°¨µµ, °íƯÀ̵µ, °í󸮷®ÀÇ ¸ÖƼÇ÷º½º ºÐ¼®ÀÌ °¡´ÉÇÕ´Ï´Ù. Àü±âÈ­ÇÐ ¹ÙÀÌ¿À¼¾¼­´Â °í°¨µµ, ƯÀ̼º, °í󸮷®ÀÇ ¸ÖƼÇ÷º½º ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ÇöÀç º¥Ä¡Å¾ ºÐ¼®±â, POC īƮ¸®Áö ¶Ç´Â ¿þ¾î·¯ºí µð¹ÙÀ̽º¿¡ ÅëÇÕÇÒ ¼ö ÀÖÀ¸¸ç, ±âÁ¸ ½ÇÇè½Ç ȯ°æ ¿Ü¿¡µµ ´Ù¾çÇÑ ¿ëµµ·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¹ÙÄÚµåÈ­µÈ ÇÁ·Îºê ÆÐ³Î ¹× ´ÙÁßÈ­µÈ ELISA Æ÷¸Ë°ú °°Àº µðÁöÅÐ ´ÙÁßÈ­ ±â¼úÀº ÇÑ ¹øÀÇ °Ë»ç·Î °ËÃâÇÒ ¼ö Àִ ǥÀûÀÇ ¼ö¸¦ È®ÀåÇϰí ÀÖÀ¸¸ç, CRISPR ±â¹Ý Áø´Ü¹ý ¹× µî¿ÂÁõÆø¹ýÀº Àúºñ¿ëÀ¸·Î ÇöÀå ¹èÄ¡°¡ °¡´ÉÇÑ ´ÙÁßÈ­ Ç÷§ÆûÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ AI ¾Ë°í¸®Áò°ú Ŭ¶ó¿ìµå ±â¹Ý ºÐ¼®ÀÌ Áø´Ü ¿öÅ©Ç÷ο쿡 ÅëÇÕµÇ¾î º¹ÀâÇÑ ´ÙÁß ´ÙÁßÈ­ µ¥ÀÌÅ͸¦ ÇØ¼®ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­, ¼ÒÇüÈ­, ½º¸¶Æ® Ä¿³ØÆ¼ºñƼ´Â Áø·á¼Ò, ÀÀ±Þ½Ç, °¡Á¤ ³» Áø´Ü¿¡ ÀûÇÕÇÑ ÈÞ´ë¿ë, »ç¿ëÀÚ Ä£È­ÀûÀÎ ¸ÖƼÇ÷º½º °Ë»ç ½Ã½ºÅÛÀ¸·ÎÀÇ ÀüȯÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ÖƼÇ÷º½º Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇÏ´Â Áúȯ ¿µ¿ª°ú ÇコÄÉ¾î ¸ðµ¨Àº?

°¨¿°¼º ÁúȯÀº ¿©ÀüÈ÷ ÁÖ¿ä ÀÀ¿ë ºÐ¾ß·Î È£Èí±â °¨¿°, ¼ºº´(STI), ¼ÒÈ­±â Áúȯ, ÆÐÇ÷Áõ °ü·Ã º´¿øÃ¼ ½Äº°¿¡ ¸ÖƼÇ÷º½º ÆÐ³ÎÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¾¾çÇÐÀº »õ·Î¿î ÃÊÁ¡À̸ç, ¸ÖƼÇ÷º½º ºÐ¼®Àº ¿©·¯ À¯ÀüÀÚ º¯È­ ¹× ¹ÙÀÌ¿À¸¶Ä¿ÀÇ µ¿½Ã °ËÃâÀÌ ÇÊ¿äÇÑ µ¹¿¬º¯ÀÌ ÇÁ·ÎÆÄÀϸµ, µ¿¹ÝÁø´Ü, ¾×ü »ý°Ë ¾ÖÇø®ÄÉÀ̼ǿ¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ª ¹× ¾Ë·¹¸£±â Áø´Üµµ ¿©·¯ Ç×ü ¹× »çÀÌÅäÄ«ÀÎ ÇÁ·ÎÆÄÀÏÀ» ÃøÁ¤ÇÏ´Â ´ÙÁßÈ­ ¸é¿ªºÐ¼®ÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù.

º´¿ø, ÀÓ»ó °Ë»ç½Ç, ÂüÁ¶ ½ÇÇè½Ç, ÀÀ±ÞÀÇ·á¼¾ÅÍ´Â ¿öÅ©Ç÷οì ÅëÇÕ°ú ½Å¼ÓÇÑ Áø´ÜÀÇ Çʿ伺À¸·Î ÀÎÇØ ¸ÖƼÇ÷º½º Áø´ÜÀÇ ÁÖ¿ä ±â°ü »ç¿ëÀÚ·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ¶ÇÇÑ, ¼Ò¸Å Ŭ¸®´Ð, ¿ø°ÝÀÇ·á ³×Æ®¿öÅ©, À̵¿½Ä ÀÇ·á À¯´ÖÀ» ÅëÇÑ ºÐ»êÇü °Ë»çÀÇ ºÎ»óÀ¸·Î ÃÖ¼ÒÇÑÀÇ ±â¼ú ±³À°À¸·Î ¿î¿µÇÒ ¼ö ÀÖ´Â ¼ÒÇü ¸ÖƼÇ÷º½º ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡¿¡¼­´Â ÀÎÇÁ¶óÀÇ Á¦¾àÀÌ ÀÖ´Â »óȲ¿¡¼­ Áø´Ü ¹üÀ§¸¦ È®ÀåÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ¹æ¹ýÀ¸·Î ½Åµå·Ò ¸ÖƼÇ÷º½º Ç÷§ÆûÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

¸ÖƼÇ÷º½º Áø´Ü ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå°ú Çõ½ÅÀÇ ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¸ÖƼÇ÷º½º Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº Áúº´ÀÇ º¹À⼺°ú °øÁߺ¸°Ç °¨½ÃÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å¼ÓÇϰí 󸮷®ÀÌ ³ôÀ¸¸ç Á¾ÇÕÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¹ßº´ ´ëºñ, Ç×±ÕÁ¦ °ü¸®, Á¾¾çÇÐ °³º°È­, ´ÙÁß ´ÙÁß ºÐ¼®ÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϱâ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. ÁõÈıº °Ë»ç ÆÐ³Î¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú °í±Þ Áø´Ü µµ±¸¿¡ ´ëÇÑ º¸Çè ȯ±Þ Àû¿ëµµ ½ÃÀå ½ÇÇà °¡´É¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

°³¹ß¾÷üµéÀº ÆÐ³Î ÄÁÅÙÃ÷ÀÇ È®Àå, °Ëü ó¸® ÀÚµ¿È­ °³¼±, ½Ã¼³ÀÇ ¿öÅ©Ç÷ο쿡 ¸ÂÃá ¸ðµâ½Ä Ç÷§Æû °³¹ß¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Áø´Ü¾à ±â¾÷, »ý¸í°øÇÐ ±â¾÷, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº Áø´Ü°ú Ä¡·á¸¦ ÅëÇÕÇÏ´Â Ç÷§ÆûÀÇ °øµ¿ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ Áúº´ ¸ð´ÏÅ͸µ, ¿ø°ÝÁö¿ë ÈÞ´ë¿ë ¸ÖƼÇ÷º½º ±â±â, µðÁöÅÐ Çコ¿ÍÀÇ ÅëÇÕÀ» ÅëÇØ ÀÌ·¯ÇÑ ±â¼úÀÇ ÀÓ»óÀû À¯¿ë¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÇコÄɾ Á¡Á¡ ´õ µ¥ÀÌÅÍ Áß½ÉÀûÀ̰í ȯÀÚ Áß½ÉÀûÀ¸·Î º¯È­ÇÔ¿¡ µû¶ó, ¸ÖƼÇ÷º½º Áø´ÜÀº Á¶±â ¹ß°ß, ¸ÂÃãÇü Ä¡·á, ½Ã½ºÅÛ Àü¹ÝÀÇ È¿À²¼º Çâ»ó¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϸç, ¼¼°è ÇコÄÉ¾î »ýŰ迡¼­ Áø´ÜÀÇ ¹Ì·¡¸¦ °áÁ¤Áþ´Â ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(±â±â ¹× ¾×¼¼¼­¸®, ŰƮ ¹× ½Ã¾à), ¿ëµµ(°¨¿°Áõ, Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ, ½ÉÀåÁúȯ, ¾Ë·¹¸£±â, ±âŸ ¿ëµµ), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø´Ü ¼¾ÅÍ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 43°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤À» Àû¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Multiplexed Diagnostics Market to Reach US$28.6 Billion by 2030

The global market for Multiplexed Diagnostics estimated at US$13.6 Billion in the year 2024, is expected to reach US$28.6 Billion by 2030, growing at a CAGR of 13.2% over the analysis period 2024-2030. Instruments & Accessories, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$15.4 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 17.3% CAGR

The Multiplexed Diagnostics market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 11.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Multiplexed Diagnostics Market - Key Trends & Drivers Summarized

Why Is Multiplexed Diagnostics Gaining Prominence in Clinical Laboratories and Point-of-Care Testing?

Multiplexed diagnostics refers to analytical platforms capable of simultaneously detecting multiple analytes-such as proteins, nucleic acids, or pathogens-from a single biological sample. This approach significantly improves diagnostic efficiency, reduces turnaround time, and conserves sample volume, making it increasingly attractive for use in infectious disease testing, oncology, autoimmune disorder screening, and pharmacogenomics. With rising demand for faster, more comprehensive, and minimally invasive testing, multiplexing technologies are becoming central to both centralized laboratories and decentralized point-of-care (POC) settings.

Compared to traditional single-analyte tests, multiplex assays enhance diagnostic yield and support syndromic testing approaches where multiple causes of a condition are investigated in parallel. For example, respiratory multiplex panels can concurrently detect influenza, SARS-CoV-2, RSV, and other pathogens-guiding treatment decisions in real time. This is particularly valuable during epidemics or in immunocompromised patient populations. As healthcare systems transition toward precision medicine and value-based care models, multiplexed diagnostics provide a means to deliver richer data at lower per-test costs and faster clinical decision cycles.

How Are Technological Advancements Enhancing Multiplexing Capabilities and Clinical Utility?

Innovations in microfluidics, biosensor miniaturization, lab-on-chip platforms, and digital detection technologies are revolutionizing the performance and accessibility of multiplexed diagnostics. Luminex bead-based systems, PCR microarrays, next-generation sequencing (NGS), and electrochemical biosensors are enabling multiplex assays with high sensitivity, specificity, and throughput. These platforms can now be integrated into benchtop analyzers, POC cartridges, or wearable devices-extending their use beyond traditional laboratory environments.

Digital multiplexing techniques, such as barcoded probe panels and multiplexed ELISA formats, are expanding the number of targets that can be detected in a single run. CRISPR-based diagnostics and isothermal amplification methods are enabling low-cost, field-deployable multiplex platforms. Simultaneously, AI algorithms and cloud-based analytics are being integrated into diagnostic workflows to interpret complex multiplex data and support actionable insights. Automation, miniaturization, and smart connectivity are driving a shift toward portable, user-friendly multiplex testing systems suitable for clinics, emergency settings, and even home diagnostics.

Which Disease Areas and Healthcare Models Are Driving Demand for Multiplexed Diagnostics?

Infectious diseases remain the dominant application area, with multiplex panels used extensively for respiratory infections, sexually transmitted infections (STIs), gastrointestinal diseases, and sepsis-related pathogen identification. Oncology is an emerging focus, where multiplexed assays are used for mutation profiling, companion diagnostics, and liquid biopsy applications that require the simultaneous detection of multiple gene alterations or biomarkers. Autoimmune and allergy diagnostics are also benefiting from multiplexed immunoassays that measure multiple antibody or cytokine profiles.

Hospitals, clinical laboratories, reference labs, and urgent care centers are the key institutional users of multiplex diagnostics, driven by the need for workflow consolidation and faster diagnostic turnaround. Additionally, the rise of decentralized testing through retail health clinics, telemedicine networks, and mobile health units is creating demand for compact multiplex systems that can be operated with minimal technical training. Low- and middle-income countries are exploring syndromic multiplex platforms as a cost-effective way to expand diagnostic reach amid infrastructure constraints.

What Is Driving Long-Term Growth and Innovation in the Multiplexed Diagnostics Market?

The growth in the multiplexed diagnostics market is driven by the global demand for rapid, high-throughput, and comprehensive diagnostic solutions amid increasing disease complexity and public health surveillance needs. Outbreak preparedness, antimicrobial stewardship, and oncology personalization are aligning to accelerate the adoption of multiplex assays. Regulatory support for syndromic testing panels and reimbursement coverage for advanced diagnostic tools are also reinforcing market viability.

Manufacturers are investing in expanding panel content, improving sample processing automation, and developing modular platforms that can be tailored to institutional workflows. Strategic partnerships between diagnostic firms, biotech companies, and healthcare providers are driving co-development of integrated diagnostic-treatment platforms. Additionally, real-time disease monitoring, portable multiplex devices for remote settings, and digital health integration are extending the clinical utility of these technologies.

As healthcare delivery becomes increasingly data-driven and patient-centric, multiplexed diagnostics will serve as an essential enabler of early detection, personalized therapy, and system-wide efficiency-defining the future of diagnostics across global healthcare ecosystems.

SCOPE OF STUDY:

The report analyzes the Multiplexed Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments & Accessories, Kits & Reagents); Application (Infectious Disease, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, Other Applications); End-User (Hospitals, Diagnostic Centers, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â